Plain-English translation of NCT06296368 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Doctors treating blood cancers now have many more medication options than ever before, which is wonderful — but it also makes choosing the right treatment more complicated. This study is testing a decision-support tool called PRIME that helps you and your doctor understand what matters most to you in your treatment, so your care plan can match your personal priorities and values.
Even with good conversations between patients and doctors, research shows that doctors don't always fully understand what their patients truly want from treatment. This tool was designed to fill that gap and help ensure that your treatment plan reflects what you care about most.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either use the PRIME decision-support tool or receive standard care before your first appointment with your oncologist. If you receive the PRIME tool, you will complete a brief survey that asks about your treatment priorities using a validated method called best-worst scaling, which generates a personalized report for you and your doctor to review. Researchers will then follow your care to see whether using this tool led to a treatment plan that better matched your personal values and priorities.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States